Skip to main content
ZTEK
NASDAQ Industrial Applications And Services

Zentek Subsidiary Triera Biosciences Launches Contract Research Organization Services

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.578
Mkt Cap
$62.16M
52W Low
$0.54
52W High
$1.841
52W Position info
7.0% above low
Off High info
69% below high
Rel. Volume
Market data snapshot near publication time

ZTEK is trading near its 52-week low of $0.54 (7.0% above the low).

Summary

Zentek's subsidiary, Triera Biosciences, has launched Contract Research Organization (CRO) services for custom aptamer discovery and biosensor enablement, aiming to generate earlier and more predictable revenue.


Key Events · Product Development and Regulatory · ZTEK

  • Launches CRO Services

    Triera Biosciences, a wholly-owned subsidiary of Zentek, has launched Contract Research Organization (CRO) services for custom aptamer discovery, biosensor enablement, and machine-learning classification.

  • Leverages Exclusive License

    The new services are backed by an exclusive, worldwide, royalty-bearing 20-year license from McMaster University for aptamer applications developed through their collaboration.

  • Targets High-Priority Markets

    Triera will target pharmaceutical, biotechnology, and diagnostics organizations in Canada, the United States, and Europe, focusing on high-priority infectious disease and oncology detection markets.

  • Asset-Light Revenue Model

    The CRO model is client-funded, allowing Triera to generate revenue while retaining ownership of underlying intellectual property, aligning with Zentek's asset-light commercialization strategy.


Analysis · ZTEK · Industrial Applications And Services

Zentek's wholly-owned subsidiary, Triera Biosciences, is launching Contract Research Organization (CRO) services, marking a significant step in commercializing its aptamer discovery and biosensor enablement platform. This initiative is designed to generate earlier and more predictable revenue for the company, leveraging an exclusive 20-year license from McMaster University. The asset-light, client-funded model reduces financial risk while targeting high-priority infectious disease and oncology detection markets, which could improve Zentek's financial runway and strategic positioning.

At the time of this filing, ZTEK was trading at $0.58 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $62.2M. The 52-week trading range was $0.54 to $1.84. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZTEK - Latest Insights

ZTEK
Jul 07, 2026, 9:40 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.476649
Real-time Price: $0.5316 info
Change: +$0.054951 (+12%) info
Market Cap: $67.311M info
ZTEK
Jul 07, 2026, 9:18 AM EDT
Source: TMX Newsfile
Importance Score:
8
Price at Filing: $0.4567
Real-time Price: $0.5316 info
Change: +$0.0749 (+16%) info
Market Cap: $67.311M info
ZTEK
Jun 29, 2026, 8:00 AM EDT
Source: TMX Newsfile
Importance Score:
8
Price at Filing: $0.449222
Real-time Price: $0.5316 info
Change: +$0.082378 (+18%) info
Market Cap: $67.311M info
ZTEK
Jun 26, 2026, 10:07 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.3901
Real-time Price: $0.5316 info
Change: +$0.1415 (+36%) info
Market Cap: $67.311M info
ZTEK
Jun 26, 2026, 9:27 AM EDT
Source: TMX Newsfile
Importance Score:
8
Price at Filing: $0.4044
Real-time Price: $0.5316 info
Change: +$0.1272 (+31%) info
Market Cap: $67.311M info